Crees findings show that weight loss is crucial to improving life expectancy in patients with PCOS, regardless of how that weight loss is achieved, but the popularity of semaglutide in our current culture makes it difficult to access due to both cost and low inventory

Clinical Trial Results STEP Trials (Semaglutide) The STEP program studied semaglutide 2.4 mg weekly in overweight/obese adults: STEP 1 : 16.9% average weight loss over 68 weeks vs 2.4% placebo STEP 2 (T2D patients): 9.6% weight loss STEP 3 (with behavioral therapy): 16.0% weight loss STEP 5 (2-year data): 15.2% sustained weight loss SURMOUNT Trials (Tirzepatide) The SURMOUNT program studied tirzepatide at 5mg, 10mg, and 15mg weekly: SURMOUNT-1 : 20.9% average weight loss at 15mg over 72 weeks vs 3.1% placebo SURMOUNT-2 (T2D patients): 14.7% at 15mg SURMOUNT-3 (with lifestyle intervention): 26.6% at highest dose SURMOUNT-4 (maintenance): continued weight loss vs weight regain on placebo Head-to-Head No large head-to-head trial has directly compared them at optimal doses for weight loss

Very Common Side Effects (may affect more than 1 in 10 people): Common Side Effects (may affect up to 1 in 10 people): Uncommon Side Effects (may affect up to 1 in 100 people): Note: This list is not exhaustive
M.ProotP.ChiangY.StumvollM.Del PratoS.et al (2019)
Can I set up automatic Ozempic refills
Human intervention studies showed that the daily consumption of polyphenol-rich grape extract for four or eight weeks reduced fasting plasma TMAO concentrations by 63.6% and 78.6%, respectively, compared with baseline (37, 38)